

Buc Seal

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032 Please type a plus sign (+) inside this box U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UTILITY PATENT APPLICATION **TRANSMITTAL**

9525 Attorney Docket No. Tanja Ligensa et al. First Inventor IGF-1 Receptor Interacting Proteins

(Only for new nonprovisions	Express I	Mail Label No.	EL91216	50928L	JS 🥦			
APPLICATION ELEMENTS			ADDRESS TO: Commissioner for Patents Box Patent Application					
See MPEP chapter 600 conce		· ·	Washington,					
Fee Transmittal For (Submit on original and a did Applicant claims son See 37 CFR 1.27.  3.  Specification (preferred arrangement see Cross Reference - Statement Regarder - Reference to see or a computer present of the computer present of the computer present - Background -	( <i>if ap</i> a. <b>[</b> X b. Sp	Computer Program (Appendix)  8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  a. Computer Readable Form (CRF)  b. Specification Sequence Listing on:  i. CD-ROM or CD-R (2 copies); or  ii. paper						
<ul> <li>Brief Summary of the Invention</li> <li>Brief Description of the Drawings (if filed)</li> </ul>			ACCOMPANYING APPLICATION PARTS					
- Detailed Description - Claim(s) - Abstract of the Disclosure			9. Assignment Papers (cover sheet & document(s))  10. 37 CFR 3.73(b) Statement (when there is an assignee) Power of Attorney					
4. Drawing(s) (35 U.S.C. 113) [ Total Sheets 7 ]			11 English Translation Document (if applicable)					
5. Oath or Declaration  a. Newly execut Copy from a p (for continuation  i. DELETIC Signed state named in the 1.63(d)(2) at  6. Application Data S  18. If a CONTINUING APPLIC or in an Application Data Sheet Continuation  Prior application information: For CONTINUATION OR DIVISIO Box 5b, is considered a part of te	ed (original or copy) prior application (37 CFR 1.63 (d)) prior application (5) prior application, see 37 CFR and 1.33(b).  Sheet. See 37 CFR 1.76  ATION, check appropriate box, and suppropriate to the set of th	of p G he prior applica nuation or divisi	Statement (IDS)/PTO-1449  13. Preliminary Amendment  14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  15. Certified Copy of Priority Document(s) (if foreign priority is claimed)  16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.  17. Other:  The requisite information below and in a preliminary amendment, of prior application No 09/453,195 Group Art Unit: 1646  Tor application, from which an oath or declaration is supplied under nor divisional application and is hereby incorporated by reference.					
	19. CORRESPOND	ENCE ADDR	ESS					
Customer Number or Bar Code Label 00151			or Correspondence address below					
Name								
Address City		State		Zip C	Code			
Country	Te	lephone		Fa	ıx _			
Name (PrintlType)	F. Aaron Dubberley A Registration No. (Attorney/Agent) 41001							
Signature	Fr. laun Onlybertus				10/30/	/2001		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Commissioner for Patents **BOX PATENT APPLICATION** Washington, D.C. 20231

Hoffmann-La Roche Inc. 340 Kingsland Street Nutley, NJ 07110 Case Docket 9525 October 30, 2001

Sir:

0

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is the patent application of

Inventor(s): Tanja Ligensa, Ralf Schumacher, Michael Weidner

## For: IGF-1 RECEPTOR INTERACTING PROTEINS

1. The fee has been calculated as shown below:

CLAIMS						
FOR	NO. FILED	NO. EXTRA	RATE	FEE		
TOTAL CLAIMS	14 - 20	0	x \$18			
INDEP. CLAIMS	3 - 3	0	x \$84			
MULTIPLE DEPENDENT CLAIMS PRESENTED + \$280						
	\$740					
TOTAL <u>\$ 740</u>						

Please charge Deposit Account No. 08-2525 in the amount noted above.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 08-2525, including those under 37 C.F.R. § 1.16 and 1.17. This sheet is provided in duplicate.

Continue to address all communications to:

George W. Johnston Hoffmann-La Roche Inc. 340 Kingsland Street Nutley, NJ 07110

Agent for Applicant(s)

F. Aaron Dubberley (Reg. No. 41001)

115111

OUR ORDER NO. 4039.

DEPOSIT ACCOUNT

NO. 08-2525





PTO/SB92 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## Certification under 37 CFR 1.10

I hereby certify that this form and all documents cited on this form are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number:

EL912160928 US

addressed to:

Commissioner for Patents Washington, D.C. 20231

Maila Sway Jewsky

on October 30, 2001 ...

Date

Marta Swaryczewsky

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Papers Submitted for Case Docket 9525 US: Patent Application Transmittal Form, Application Data Sheet, Fee Transmittal Form, Specification, Sequence Listing, Diskette, Statement Under 37 CFR 1.821 or 1.825, Drawings, Information Disclosure Statement with PTO Form 1449

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.